NCT06289959View on ClinicalTrials.gov

Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 25, 2024

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2029

Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
DIAGNOSTIC_TEST

cfDNA

After achieving complete metabolic remission (Lugano response assessment criteria) following 6 cycles of R-CHOP-like chemotherapy, patients undergo plasma cfDNA testing upon enrollment，and the follow-up treatment plans are based on cfDNA results.

Trial Locations (1)

215000

The Second Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Soochow University

OTHER

NCT06289959 - Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL | Biotech Hunter | Biotech Hunter